What is Dasatinib?
Category: Prescription Drugs
Most popular types: Sprycel
Dasatinib, brand name Sprycel®, is a tyrosine kinase inhibitor used to treat Ph+CML and Ph+ALL when resistance or intolerance develops to prior therapy. It targets most imatinib-resistant BCR-ABL mutation by distinctly binding to ABL-kinase to halt the proliferation of leukemia cells.
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Chronic myeloid leukemia | 15 | 11 | |
| Acute lymphocytic leukemia | 7 | 0 | |
| Adenocarcinoma (non-small cell lung cancer) | 1 | 0 | |
| Participate in clinical trial | 1 | 0 |
- Major
- Moderate
- Slight
- None
- Can't tell
Side effects
Side effects as an overall problem
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 0 | |
| Moderate | 5 | |
| Mild | 5 | |
| None | 1 |
Commonly reported side effects and conditions associated with Dasatinib
| Side effect | Patients | Percentage |
|---|---|---|
| Headaches | 2 | |
| Pleural effusion | 2 | |
| Anxious mood | 1 | |
| Black stool | 1 | |
| Bone pain | 1 | |
| Dizziness | 1 |
Why patients stopped taking Dasatinib
Multiple reasons could be selected
| Reason | Patients | Percentage |
|---|---|---|
| Did not seem to work | 2 | |
| Doctor's advice | 1 |
Duration
Stopped taking Dasatinib
| Duration | Patients | Percentage |
|---|---|---|
| 1 - 2 years | 1 | |
| 2 - 5 years | 1 |
What people switch to and from
Patients started taking Dasatinib after stopping:
| Treatment | Patients | Percentage |
|---|---|---|
| Imatinib (Gleevec) | 3 |
Patients stopped taking Dasatinib and switched to:
| Treatment | Patients | Percentage |
|---|---|---|
| Nilotinib (Tasigna) | 1 |
Last updated: